TuHURA Biosciences (HURA) News Today

TuHURA Biosciences, Inc. (NASDAQ: HURA) is under pressure as investors weigh reduced earnings forecasts from HC Wainwright against a favorable analyst rating.

• Positive Sentiment: Citizens JMP initiated or reiterated a “Market Outperform” rating on TuHURA, signaling confidence in the company’s longer-term prospects. TuHURA Biosciences Earns Market Outperform Rating from Citizens JMP
• Neutral Sentiment: HC Wainwright projected continued losses in 2027, including quarterly EPS of approximately ($0.15) through the first three quarters and ($0.16) in the fourth quarter, resulting in a full-year loss of about ($0.61) per share. These estimates provide a forward earnings baseline but indicate that profitability is not expected in the near term.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecasts: Q3 to ($0.14) from ($0.13), Q4 to ($0.15) from ($0.13), and full-year 2026 to ($0.55) from ($0.50). The downward revisions suggest weaker expected results or higher anticipated operating costs.

Overall, the negative stock reaction appears primarily tied to the downward revisions and expectations for ongoing losses. The Citizens JMP upgrade provides a positive counterpoint, but investors may remain focused on TuHURA’s cash needs, development progress, and ability to narrow losses.